Kristina K. Peachman

Dr. Kristina K. Peachman

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
GJGordon Joyce
Gordon Joyce
HKHannah A. D. King
Hannah A. D. King
IEInes Elakhal-Naouar
Ines Elakhal-Naouar
AAAslaa Ahmed
Aslaa Ahmed
KPKristina K. Peachman
Kristina K. Peachman
KMKayvon Modjarrad
Kayvon Modjarrad
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (T H 1)–biased CD4 T H response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

1 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
HKHannah A. D. King
Hannah A. D. King
GJGordon Joyce
Gordon Joyce
ILInes Lakhal-Naouar
Ines Lakhal-Naouar
AAAslaa Ahmed
Aslaa Ahmed
CCCamila Macedo Cincotta
Camila Macedo Cincotta
DBDiane L. Bolton
Diane L. Bolton
Significance: The emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the efficacy of current COVID-19 vaccines is a major threat to pandemic control. We evaluate a SARS-CoV-2 spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model that addresses the need for a next-generation vaccine with increased pan-SARS breadth of coverage. RFN, adjuvanted with a liposomal-QS21 formulation (ALFQ), elicits humoral and cellular immune responses with excellent breadth and potency against SARS-CoV-2 VOCs and SARS-CoV-1, and protects against high-dose respiratory tract challenge with SARS-CoV-2. Our results support consideration of RFN for vaccine development against multiple concerning members of the Sarbecovirus subgenus of Betacoronaviruses .

1 February 2021 in iScience
Verified
Journal Article
Open access
ICIsabela Silva de Castro
Isabela Silva de Castro
GGGiacomo Gorini
Giacomo Gorini
RMRosemarie Mason
Rosemarie Mason
JGJason Gorman
Jason Gorman
MBMassimiliano Bissa
Massimiliano Bissa
GFGenoveffa Franchini
Genoveffa Franchini
The efficacy of ALVAC-based HIV and SIV vaccines in humans and macaques correlates with antibodies to envelope variable region 2 (V2). We show here that vaccine-induced antibodies to SIV variable region 1 (V1) inhibit anti-V2 antibody-mediated cytotoxicity and reverse their ability to block V2 peptide interaction with the α4β7 integrin. SIV vaccines engineered to delete V1 and favor an α helix, rather than a β sheet V2 conformation, induced V2-specific ADCC correlating with decreased risk of SIV acquisition. Removal of V1 from the HIV-1 clade A/E A244 envelope resulted in decreased binding to antibodies recognizing V2 in the β sheet conformation. Thus, deletion of V1 in HIV envelope immunogens may improve antibody responses to V2 virus vulnerability sites and increase the efficacy of HIV vaccine candidates.

4 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
SJSara C. Johnston
Sara C. Johnston
KRKeersten M. Ricks
Keersten M. Ricks
ILInes Lakhal-Naouar
Ines Lakhal-Naouar
AJAlexandra Jay
Alexandra Jay
CSCaroline Subra
Caroline Subra
LPLouise Pitt
Louise Pitt
The COVID-19 pandemic has had a staggering impact on social, economic, and public health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the etiologic agent of COVID-19) has been rapid. However, novel strategies are still necessary to slow the pandemic, and this includes new approaches to vaccine development and/or delivery that will improve vaccination compliance and demonstrate efficacy against emerging variants. Here, we report on the immunogenicity and efficacy of a SARS-CoV-2 vaccine comprising stabilized, pre-fusion spike protein trimers displayed on a ferritin nanoparticle (SpFN) adjuvanted with either conventional aluminum hydroxide or the Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque COVID-19 model. Vaccination resulted in robust cell-mediated and humoral responses and a significant reduction in lung lesions following SARS-CoV-2 infection. The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.

12 January 2011 in Journal of Liposome Research
Verified
Journal Article
Closed access
PDF file
CACarl R Alving
Carl R Alving
MRMangalo Rao
Mangalo Rao
KPKristina K. Peachman
Kristina K. Peachman
LALudmila Asher
Ludmila Asher
VRVenigalla B Rao
Venigalla B Rao
A unique formulation is described comprising liposomes containing glucosyl ceramide (GluCer) in the lipid bilayer to which bacteriophage T4 was attached. Binding of the phage T4 did not occur to glycolipids, such as galactosyl ceramide, containing an aldose in which the C-2 or C-4 conformations were not identical to glucose. These results strongly support previous proposals that glucose is a major receptor moiety for T4 binding to Escherichia coli. By using the binding of T4 to liposomal GluCer, we further describe a formulation that can be used as a self-assembling combined antigen and adjuvant carrier. A peptide antigen derived from C-trimer (Ct) of HIV-1 gp41 was fused to the highly antigenic outer capsid protein (Hoc), a nonessential protein of T4 that spontaneously binds to the T4 capsid. This resulted in display of the Ct-Hoc construct on the T4 capsid, and specific binding of a human monoclonal antibody that recognizes a peptide sequence of Ct was demonstrated. Liposomes containing monophosphoryl lipid A (MPLA) have been demonstrated to have potent adjuvant activities for experimental vaccines both in humans and animals, and because of this, mice were immunized with the Ct-Hoc-T4 construct that was bound to liposomes containing both GluCer and MPLA, resulting in the induction of high titers of Ct-specific antibodies. We conclude that liposomes containing both GluCer and MPLA can spontaneously bind to a construct of T4 that displays antigens that spontaneously binds to the capsid of T4 bacteriophage. This formulation could be utilized as an easily manufactured self-assembling antigen and adjuvant carrier.

22 October 2009 in Retrovirology
Verified
Journal Article
Open access
PDF file
KPKristina K. Peachman
Kristina K. Peachman
LWL Wieczorek
L Wieczorek
VPVr Polonis
Vr Polonis
CACr Alving
Cr Alving
MRM Rao
M Rao